PT-141 (Bremelanotide): Melanocortin Receptor Research and Preclinical Studies

PT-141 Research Overview: Scientific Review of Bremelanotide (PT-141) Peptide Studies

PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist derived from Melanotan II. In peptide research, it is primarily studied for its interactions with central nervous system pathways, particularly melanocortin receptors (MC4R and MC1R), and its potential influence on sexual arousal and desire mechanisms. This article summarizes published scientific literature on PT-141 / Bremelanotide, focusing exclusively on research findings. PT-141 is for research purposes only and is not intended for human therapeutic use outside of approved pharmaceutical contexts. It is not FDA- or TGA-approved as a research peptide for general laboratory distribution in unregulated settings.

Disclaimer: This content is for educational purposes and summarizes peer-reviewed studies only. It does not provide medical advice, dosage recommendations, or endorsements for human use. All peptides are sold strictly for laboratory research. Consult regulatory authorities and qualified professionals for any research involving this compound. For high-purity research peptides, visit thepeptideco.online.

PT-141 in Sexual Dysfunction Research

PT-141 has been investigated in clinical and preclinical studies for its central mechanisms in modulating sexual desire and arousal, differing from peripherally acting PDE-5 inhibitors. Research distinguishes between the FDA-approved pharmaceutical formulation (Vyleesi / bremelanotide) for a specific indication in premenopausal women with generalized hypoactive sexual desire disorder (HSDD) and the broader research peptide context.

• Women’s Health Research (HSDD): Phase 3 clinical trials (e.g., RECONNECT studies) evaluated subcutaneous bremelanotide (1.75 mg) and supported regulatory approval for the approved drug product in targeted populations. Studies reported increases in sexual desire scores and reductions in distress in controlled settings.
• Men’s Health and ED Research: Preclinical and early clinical investigations have explored PT-141 in models of erectile dysfunction, including cases with incomplete response to other agents. Some studies report erectile response rates in specific experimental conditions, with onset and duration data published in the literature. Synergy explorations with other compounds remain investigational.

Mechanism of Action Studies

Research indicates that PT-141 acts as an agonist at melanocortin receptors (primarily MC4R) in the hypothalamus and central nervous system, influencing dopamine release and neural pathways associated with motivation and arousal. This central mechanism is a key focus of ongoing peptide neuroscience studies. Ancillary effects on MC1R (e.g., pigmentation pathways) are also documented in literature.

Emerging Research Areas

• Delivery Methods: Studies compare subcutaneous injection with nasal spray formulations for pharmacokinetics and onset in research models. Nasal delivery is explored for convenience in laboratory protocols.
• Broader Investigations: Limited preclinical work has examined potential neuroprotective or other effects in animal models, though sexual function pathways remain the dominant research focus.
• Safety and Tolerability Data: Published clinical studies report common adverse events such as flushing, nausea, and headache, generally transient. Long-term data from approved pharmaceutical use exists for specific indications, while research peptide safety profiles require case-by-case evaluation in controlled laboratory settings. Blood pressure effects have been noted in some studies.

Practical Considerations in Research

Typical research protocols reference doses in the 1–2 mg range subcutaneously or via nasal routes, depending on the specific study design. Variables such as purity (aim for ≥99% where possible), administration route, and experimental model significantly impact outcomes. PT-141 must be handled according to all biosafety and regulatory requirements.

For Research Use Only: Source high-quality PT-141 from reputable laboratory suppliers.

Peptide Technology / ThePeptideCo Resources (Research Only)

1. PT-141 10 mg – Research Grade High-purity peptide for laboratory sexual dysfunction and melanocortin receptor studies. https://www.thepeptideco.online/product/pt-141-10mg
2. Peptide Research Catalog Browse PT-141 alongside other research peptides. https://www.thepeptideco.online/shop

Future Directions in PT-141 Research

PT-141 continues to serve as a valuable tool in neuroscience and sexual health research due to its unique central melanocortin pathway activity. Ongoing studies aim to refine delivery systems, explore combination approaches, and expand mechanistic understanding. Substantial further research is needed for any expanded applications.

Keywords: PT-141, Bremelanotide, PT141 research, melanocortin agonist, sexual dysfunction research, HSDD studies, MC4R peptide, bremelanotide mechanism, research peptides, libido research peptide.

This article summarizes scientific literature and does not promote or endorse human consumption. Compliance with FDA, TGA, and all applicable research regulations is required. Research peptides are strictly for laboratory use.